Show overview
The Long Run with Luke Timmerman has been publishing since 2017, and across the 9 years since has built a catalogue of 208 episodes. That works out to roughly 230 hours of audio in total. Releases follow a fortnightly cadence.
Episodes typically run an hour to ninety minutes — most land between 1h and 1h 10m — and the run-time is fairly consistent across the catalogue. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 1 weeks ago, with 19 episodes already out so far this year.
From the publisher
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Latest Episodes
View all 208 episodesEp210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Ep201: Jeremy Levin on Biotech in the Balance
Ep200: Richard Pops on Orexin Drugs For Sleep Disorders & More
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Ep192: Kate Haviland on Following the Science to Precision Immunology
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).